iStar Medical said today that it raised a $11.4 million Series B round for the implants it’s developing to treat glaucoma. Wavre, Belgium-based iStar said its pipeline, including the 1st-generation StarFlo implant, is based on the Star material it created. The €10 million Series B round will go toward the development and CE Mark trial of its 2nd-generation […]
iStar Medical said it landed about $5.4 million (€4 million) from a Series A funding round it plans to use to support its StarFlo ophthalmic implant.
The StarFlo device is designed to treat glaucoma by helping the eye drain excess fluid using iStar Medical’s Star biomaterial.
Isnes, Belgium-based iStar said it plans to use the proceeds for more clinical studies, regulatory submission and clearance in the U.S. and to support its research & development pipeline. iStar is a spinout of Healionics Corp.